GlassScriptPhysician profile
Michael I Asike
NPI 1619014214
$8,326.55
in general payments reported to CMS, 2019-2025
38 companies · $1,584 in 2025
The $1,584 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $385 · 2020: $341 · 2021: $535 · 2022: $1,428 · 2023: $2,443 · 2024: $1,611 · 2025: $1,584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,477 · Education: $161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,477.40 |
| Education | $160.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,132.47 | 2019-2025 | Linzess, Rinvoq, Viberzi |
| Janssen Biotech, INC. | $716.37 | 2019-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $659.81 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Genzyme Corporation | $518.02 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $510.75 | 2019-2025 | Xifaxan, Trulance |
| Celgene Corporation | $431.86 | 2021-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $321.87 | 2022-2025 | Dupixent |
| Qol Medical, LLC | $307.55 | 2019-2024 | Sucraid, Sucraid |
| Intercept Pharmaceuticals, INC. | $302.19 | 2023-2025 | Ocaliva |
| Pfizer INC. | $302.08 | 2021-2025 | |
| Madrigal Pharmaceuticals | $265.45 | 2024-2025 | Rezdiffra, Resmetirom |
| Celltrion USA INC. | $191.73 | 2024-2025 | Vegzelma, Zymfentra |
| Ardelyx, INC. | $182.10 | 2022-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $154.52 | 2022-2024 | Linzess |
| Nestle Healthcare Nutrition INC. | $142.58 | 2021-2023 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $130.47 | 2023-2025 | Zenpep |
| Lilly USA, LLC | $104.18 | 2024-2025 | Omvoh |
| Daiichi Sankyo INC. | $102.40 | 2024 | Injectafer |
| Olympus America INC. | $101.25 | 2019-2024 | Hanarostent Esophagus Tts(Ccc), Endoclot Phs |
| Phathom Pharmaceuticals, INC. | $95.49 | 2024-2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $94.85 | 2022-2024 | Rebyota |
| Gilead Sciences, INC. | $91.71 | 2024-2025 | |
| Braintree Laboratories, INC. | $78.74 | 2021-2025 | Suflave, Sutab |
| Organon LLC | $68.41 | 2023-2025 | Renflexis, Hadlima |
| Ethicon US, LLC | $42.71 | 2025 | Echelon; Endopath |
| Merck Sharp & Dohme LLC | $42.49 | 2021-2023 | Zinplava, Dificid |
| Fujifilm Healthcare Americas Corporation | $33.92 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $28.73 | 2025 | Iqirvo |
| Eisai INC. | $24.61 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.25 | 2024 | Cyltezo |
| Allergan, INC. | $18.74 | 2019 | |
| Shield Therapeutics INC | $18.46 | 2023 | Accrufer |
| Sandoz INC. | $17.73 | 2023 | Hyrimoz |
| Boston Scientific Corporation | $17.23 | 2019 | |
| Fresenius Kabi USA, LLC | $16.42 | 2023 | Idacio |
| Alnylam Pharmaceuticals INC. | $13.25 | 2023 | Givlaari |
| Redhill Biopharma INC. | $12.39 | 2022 | |
| Medtronic, INC. | $11.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Asike listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.